| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 437 | 2025 | 824 | 54.830 |
Why?
|
| Skin Neoplasms | 231 | 2024 | 798 | 31.510 |
Why?
|
| Interferon-alpha | 101 | 2022 | 220 | 15.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 84 | 2024 | 1232 | 8.480 |
Why?
|
| Antineoplastic Agents | 93 | 2024 | 1662 | 7.710 |
Why?
|
| Cancer Vaccines | 45 | 2021 | 179 | 7.510 |
Why?
|
| Proto-Oncogene Proteins B-raf | 31 | 2025 | 164 | 5.130 |
Why?
|
| Immunotherapy | 55 | 2025 | 657 | 5.010 |
Why?
|
| Ipilimumab | 29 | 2024 | 45 | 4.530 |
Why?
|
| Neoplasm Staging | 91 | 2024 | 1211 | 4.220 |
Why?
|
| Adjuvants, Immunologic | 26 | 2024 | 375 | 4.110 |
Why?
|
| Chemotherapy, Adjuvant | 56 | 2024 | 353 | 3.940 |
Why?
|
| Biomarkers, Tumor | 36 | 2024 | 1437 | 3.590 |
Why?
|
| Programmed Cell Death 1 Receptor | 26 | 2024 | 113 | 3.360 |
Why?
|
| Recombinant Proteins | 84 | 2018 | 1385 | 3.270 |
Why?
|
| Antibodies, Monoclonal | 29 | 2018 | 1009 | 3.230 |
Why?
|
| Antigens, Neoplasm | 32 | 2024 | 381 | 3.230 |
Why?
|
| Dacarbazine | 32 | 2021 | 86 | 2.990 |
Why?
|
| CD8-Positive T-Lymphocytes | 23 | 2024 | 387 | 2.820 |
Why?
|
| Humans | 498 | 2025 | 123258 | 2.760 |
Why?
|
| Neoadjuvant Therapy | 14 | 2024 | 322 | 2.680 |
Why?
|
| Disease-Free Survival | 53 | 2024 | 858 | 2.670 |
Why?
|
| Antineoplastic Agents, Immunological | 11 | 2024 | 100 | 2.520 |
Why?
|
| Interferons | 19 | 2019 | 122 | 2.480 |
Why?
|
| Middle Aged | 205 | 2025 | 26087 | 2.440 |
Why?
|
| Aged | 175 | 2025 | 19194 | 2.310 |
Why?
|
| Oximes | 13 | 2024 | 48 | 2.300 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 10 | 2017 | 66 | 2.270 |
Why?
|
| Interleukin-2 | 29 | 2022 | 224 | 2.220 |
Why?
|
| Prognosis | 72 | 2024 | 4510 | 2.180 |
Why?
|
| Adult | 188 | 2025 | 29100 | 2.150 |
Why?
|
| Aged, 80 and over | 81 | 2024 | 6392 | 2.000 |
Why?
|
| Neoplasm Metastasis | 35 | 2025 | 654 | 1.980 |
Why?
|
| Imidazoles | 12 | 2024 | 193 | 1.960 |
Why?
|
| Antibodies, Monoclonal, Humanized | 26 | 2024 | 489 | 1.920 |
Why?
|
| Survival Analysis | 54 | 2021 | 1473 | 1.900 |
Why?
|
| Male | 231 | 2025 | 60336 | 1.890 |
Why?
|
| Dendritic Cells | 15 | 2021 | 402 | 1.880 |
Why?
|
| Female | 238 | 2025 | 65619 | 1.820 |
Why?
|
| CTLA-4 Antigen | 16 | 2024 | 51 | 1.810 |
Why?
|
| Antigens, CD | 18 | 2024 | 419 | 1.770 |
Why?
|
| Sentinel Lymph Node Biopsy | 15 | 2024 | 54 | 1.760 |
Why?
|
| Neoplasms | 30 | 2023 | 2758 | 1.730 |
Why?
|
| Pyridones | 11 | 2024 | 112 | 1.700 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2022 | 523 | 1.670 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2022 | 73 | 1.640 |
Why?
|
| Pyrimidinones | 9 | 2024 | 40 | 1.540 |
Why?
|
| Lymphatic Metastasis | 29 | 2020 | 401 | 1.520 |
Why?
|
| Clinical Trials as Topic | 36 | 2020 | 1084 | 1.510 |
Why?
|
| Antineoplastic Agents, Alkylating | 10 | 2014 | 99 | 1.470 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 14 | 2024 | 105 | 1.470 |
Why?
|
| Interferon-gamma | 27 | 2024 | 499 | 1.450 |
Why?
|
| Nevus, Pigmented | 9 | 2020 | 32 | 1.410 |
Why?
|
| Vaccines, Subunit | 7 | 2017 | 66 | 1.410 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2024 | 1006 | 1.380 |
Why?
|
| Uveal Neoplasms | 9 | 2024 | 54 | 1.350 |
Why?
|
| Combined Modality Therapy | 31 | 2024 | 1239 | 1.350 |
Why?
|
| Molecular Targeted Therapy | 14 | 2025 | 351 | 1.310 |
Why?
|
| Dasatinib | 2 | 2021 | 40 | 1.300 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2021 | 713 | 1.270 |
Why?
|
| Treatment Outcome | 72 | 2024 | 12169 | 1.260 |
Why?
|
| Interferon Type I | 16 | 2016 | 107 | 1.230 |
Why?
|
| Benzimidazoles | 4 | 2015 | 129 | 1.220 |
Why?
|
| Drug Administration Schedule | 27 | 2018 | 726 | 1.190 |
Why?
|
| Nevus | 8 | 2020 | 35 | 1.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 20 | 2021 | 473 | 1.170 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2021 | 1689 | 1.160 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2023 | 767 | 1.140 |
Why?
|
| B7-H1 Antigen | 3 | 2019 | 109 | 1.120 |
Why?
|
| Mutation | 25 | 2024 | 5765 | 1.120 |
Why?
|
| Immunologic Factors | 9 | 2019 | 179 | 1.110 |
Why?
|
| Young Adult | 40 | 2024 | 8868 | 1.090 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2023 | 1118 | 1.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2018 | 94 | 1.050 |
Why?
|
| Survival Rate | 40 | 2020 | 2002 | 1.050 |
Why?
|
| Brain Neoplasms | 20 | 2023 | 1236 | 1.030 |
Why?
|
| Lymphoid Tissue | 2 | 2024 | 45 | 1.030 |
Why?
|
| Telomerase | 5 | 2022 | 161 | 1.020 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2016 | 236 | 1.020 |
Why?
|
| Quinolines | 3 | 2021 | 96 | 1.010 |
Why?
|
| Membrane Proteins | 17 | 2021 | 1523 | 1.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2024 | 1872 | 0.990 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2024 | 1080 | 0.960 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 83 | 0.950 |
Why?
|
| Quality of Life | 13 | 2023 | 1933 | 0.920 |
Why?
|
| Double-Blind Method | 20 | 2024 | 1601 | 0.900 |
Why?
|
| Tumor Microenvironment | 14 | 2024 | 535 | 0.870 |
Why?
|
| Cell Line, Tumor | 29 | 2024 | 3285 | 0.870 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2021 | 256 | 0.860 |
Why?
|
| Kidney Neoplasms | 14 | 2009 | 429 | 0.850 |
Why?
|
| Lymphocyte Activation | 17 | 2024 | 684 | 0.850 |
Why?
|
| Epitopes, T-Lymphocyte | 11 | 2010 | 125 | 0.830 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2017 | 216 | 0.830 |
Why?
|
| Receptor, Interferon alpha-beta | 4 | 2019 | 10 | 0.830 |
Why?
|
| STAT3 Transcription Factor | 5 | 2008 | 216 | 0.800 |
Why?
|
| Peptide Fragments | 11 | 2015 | 747 | 0.800 |
Why?
|
| Autophagosomes | 2 | 2021 | 24 | 0.800 |
Why?
|
| Follow-Up Studies | 34 | 2024 | 5056 | 0.790 |
Why?
|
| Gene Expression Profiling | 14 | 2024 | 1680 | 0.790 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 644 | 0.790 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 10 | 0.780 |
Why?
|
| Killer Cells, Natural | 16 | 2020 | 319 | 0.780 |
Why?
|
| Radiosurgery | 9 | 2017 | 106 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2022 | 654 | 0.780 |
Why?
|
| Receptors, Death Domain | 1 | 2021 | 1 | 0.770 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 221 | 0.770 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2020 | 81 | 0.760 |
Why?
|
| Signal Transduction | 23 | 2024 | 4499 | 0.750 |
Why?
|
| Sulfonamides | 7 | 2017 | 259 | 0.750 |
Why?
|
| Dysplastic Nevus Syndrome | 9 | 2018 | 21 | 0.740 |
Why?
|
| Practice Guidelines as Topic | 6 | 2021 | 1253 | 0.740 |
Why?
|
| Sentinel Lymph Node | 2 | 2017 | 7 | 0.730 |
Why?
|
| GTP Phosphohydrolases | 4 | 2018 | 142 | 0.730 |
Why?
|
| Lymph Nodes | 13 | 2017 | 376 | 0.730 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 348 | 0.720 |
Why?
|
| Autoimmunity | 5 | 2014 | 172 | 0.710 |
Why?
|
| Disease Progression | 21 | 2023 | 2030 | 0.690 |
Why?
|
| Neoplasm Proteins | 15 | 2019 | 668 | 0.690 |
Why?
|
| Toll-Like Receptor 9 | 3 | 2021 | 18 | 0.690 |
Why?
|
| Adolescent | 43 | 2024 | 19133 | 0.690 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 4 | 2024 | 4 | 0.680 |
Why?
|
| Anticarcinogenic Agents | 1 | 2020 | 55 | 0.670 |
Why?
|
| HLA-DR Antigens | 12 | 2007 | 75 | 0.670 |
Why?
|
| Proportional Hazards Models | 16 | 2019 | 1304 | 0.660 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2022 | 13 | 0.650 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2017 | 207 | 0.650 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 483 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 2586 | 0.620 |
Why?
|
| BCG Vaccine | 6 | 2008 | 108 | 0.620 |
Why?
|
| Isothiocyanates | 1 | 2018 | 13 | 0.610 |
Why?
|
| Brassica | 1 | 2018 | 14 | 0.610 |
Why?
|
| Cell Proliferation | 9 | 2020 | 2310 | 0.600 |
Why?
|
| Autoantibodies | 3 | 2014 | 426 | 0.590 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2015 | 144 | 0.580 |
Why?
|
| HLA-A2 Antigen | 2 | 2015 | 25 | 0.580 |
Why?
|
| Time Factors | 29 | 2021 | 6222 | 0.580 |
Why?
|
| T-Lymphocytes, Cytotoxic | 7 | 2024 | 501 | 0.580 |
Why?
|
| Nurse's Role | 1 | 2017 | 35 | 0.570 |
Why?
|
| Meta-Analysis as Topic | 5 | 2020 | 153 | 0.570 |
Why?
|
| Vaginal Neoplasms | 1 | 2017 | 14 | 0.560 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 17 | 0.560 |
Why?
|
| Plant Extracts | 1 | 2018 | 120 | 0.550 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 1591 | 0.540 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 2013 | 135 | 0.540 |
Why?
|
| Freund's Adjuvant | 5 | 2017 | 26 | 0.540 |
Why?
|
| Risk Factors | 25 | 2023 | 10035 | 0.540 |
Why?
|
| Benzamides | 3 | 2018 | 105 | 0.540 |
Why?
|
| MAP Kinase Signaling System | 4 | 2020 | 315 | 0.530 |
Why?
|
| G(M2) Ganglioside | 4 | 2014 | 4 | 0.530 |
Why?
|
| Oncolytic Virotherapy | 3 | 2023 | 81 | 0.520 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 216 | 0.520 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2011 | 20 | 0.510 |
Why?
|
| Evidence-Based Medicine | 6 | 2017 | 623 | 0.510 |
Why?
|
| Immunohistochemistry | 14 | 2020 | 1687 | 0.500 |
Why?
|
| Monitoring, Immunologic | 2 | 2014 | 17 | 0.500 |
Why?
|
| Th1 Cells | 5 | 2019 | 152 | 0.500 |
Why?
|
| Community Health Services | 1 | 2016 | 88 | 0.500 |
Why?
|
| Interleukin-18 | 4 | 2011 | 60 | 0.490 |
Why?
|
| Head and Neck Neoplasms | 9 | 2020 | 481 | 0.490 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 94 | 0.490 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2017 | 70 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 334 | 0.470 |
Why?
|
| Risk Assessment | 14 | 2023 | 3336 | 0.460 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2014 | 27 | 0.460 |
Why?
|
| T-Lymphocytes | 13 | 2021 | 1693 | 0.450 |
Why?
|
| Peptides | 5 | 2013 | 791 | 0.450 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 37 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2018 | 413 | 0.450 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2013 | 54 | 0.450 |
Why?
|
| Lymphocyte Subsets | 3 | 2010 | 38 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 714 | 0.440 |
Why?
|
| Skin | 5 | 2020 | 507 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2010 | 667 | 0.440 |
Why?
|
| Prospective Studies | 17 | 2024 | 6030 | 0.430 |
Why?
|
| Apoptosis | 9 | 2014 | 1786 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1525 | 0.430 |
Why?
|
| Cytokines | 8 | 2023 | 1282 | 0.430 |
Why?
|
| STAT1 Transcription Factor | 5 | 2011 | 69 | 0.420 |
Why?
|
| Azacitidine | 1 | 2012 | 54 | 0.410 |
Why?
|
| Animals | 39 | 2024 | 33847 | 0.410 |
Why?
|
| Quinolones | 2 | 2012 | 53 | 0.400 |
Why?
|
| Cisplatin | 9 | 2017 | 242 | 0.400 |
Why?
|
| Forkhead Transcription Factors | 5 | 2017 | 365 | 0.400 |
Why?
|
| Biopsy | 9 | 2024 | 1236 | 0.390 |
Why?
|
| Melanocytes | 7 | 2016 | 47 | 0.390 |
Why?
|
| Carboplatin | 7 | 2015 | 75 | 0.390 |
Why?
|
| Drug Synergism | 8 | 2021 | 239 | 0.390 |
Why?
|
| Biostatistics | 1 | 2011 | 10 | 0.390 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2011 | 19 | 0.390 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2011 | 60 | 0.390 |
Why?
|
| Chemistry, Clinical | 1 | 2011 | 13 | 0.380 |
Why?
|
| Case-Control Studies | 7 | 2022 | 3239 | 0.380 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 406 | 0.370 |
Why?
|
| Consensus | 8 | 2020 | 610 | 0.370 |
Why?
|
| Neovascularization, Pathologic | 3 | 2007 | 240 | 0.370 |
Why?
|
| Purines | 1 | 2011 | 107 | 0.370 |
Why?
|
| Biomarkers | 7 | 2023 | 2952 | 0.360 |
Why?
|
| Precancerous Conditions | 6 | 2014 | 283 | 0.360 |
Why?
|
| Thionucleotides | 2 | 2007 | 19 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 883 | 0.350 |
Why?
|
| Drug Discovery | 1 | 2011 | 170 | 0.350 |
Why?
|
| Exosomes | 2 | 2021 | 43 | 0.340 |
Why?
|
| Retrospective Studies | 22 | 2024 | 16068 | 0.340 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2007 | 75 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 5 | 2022 | 1340 | 0.330 |
Why?
|
| Indoles | 5 | 2014 | 180 | 0.330 |
Why?
|
| Niacinamide | 6 | 2015 | 24 | 0.330 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2018 | 154 | 0.330 |
Why?
|
| Extracellular Vesicles | 2 | 2021 | 45 | 0.330 |
Why?
|
| Transcriptome | 5 | 2023 | 903 | 0.320 |
Why?
|
| Vaccination | 7 | 2020 | 947 | 0.320 |
Why?
|
| Phenylurea Compounds | 6 | 2015 | 48 | 0.320 |
Why?
|
| Proteins | 4 | 2021 | 1040 | 0.320 |
Why?
|
| Dermatologic Surgical Procedures | 3 | 2019 | 45 | 0.310 |
Why?
|
| S100 Proteins | 1 | 2008 | 45 | 0.310 |
Why?
|
| Drug Evaluation | 14 | 2004 | 111 | 0.310 |
Why?
|
| Patient Selection | 6 | 2020 | 683 | 0.310 |
Why?
|
| Antigens, Differentiation | 2 | 2007 | 63 | 0.310 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 72 | 0.310 |
Why?
|
| Immunotherapy, Active | 3 | 2008 | 18 | 0.310 |
Why?
|
| Immunoglobulin G | 3 | 2007 | 768 | 0.300 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 89 | 0.300 |
Why?
|
| Interleukin-17 | 1 | 2008 | 118 | 0.300 |
Why?
|
| Biomedical Research | 5 | 2021 | 517 | 0.290 |
Why?
|
| Paclitaxel | 5 | 2015 | 120 | 0.290 |
Why?
|
| L-Lactate Dehydrogenase | 5 | 2020 | 61 | 0.290 |
Why?
|
| Multivariate Analysis | 7 | 2010 | 1414 | 0.280 |
Why?
|
| Lymph Node Excision | 6 | 2020 | 157 | 0.280 |
Why?
|
| Integrins | 1 | 2007 | 82 | 0.280 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 824 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 258 | 0.270 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 2024 | 262 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2024 | 479 | 0.270 |
Why?
|
| Sunbathing | 2 | 2020 | 3 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2022 | 67 | 0.260 |
Why?
|
| Mice | 23 | 2024 | 17552 | 0.260 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 109 | 0.260 |
Why?
|
| Choroid Neoplasms | 5 | 2008 | 25 | 0.260 |
Why?
|
| Immune Tolerance | 3 | 2020 | 145 | 0.260 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2021 | 74 | 0.260 |
Why?
|
| Isotretinoin | 1 | 2005 | 26 | 0.250 |
Why?
|
| Pilot Projects | 6 | 2021 | 1389 | 0.250 |
Why?
|
| Spinal Neoplasms | 1 | 2006 | 59 | 0.250 |
Why?
|
| Melanoma, Experimental | 7 | 2024 | 29 | 0.250 |
Why?
|
| Biological Therapy | 2 | 2007 | 20 | 0.250 |
Why?
|
| Tumor Escape | 3 | 2015 | 61 | 0.250 |
Why?
|
| HLA Antigens | 4 | 2012 | 243 | 0.250 |
Why?
|
| Th2 Cells | 3 | 2005 | 187 | 0.240 |
Why?
|
| United States | 22 | 2018 | 10652 | 0.240 |
Why?
|
| Smallpox Vaccine | 1 | 2005 | 36 | 0.240 |
Why?
|
| Eye Neoplasms | 2 | 2004 | 50 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 152 | 0.240 |
Why?
|
| Immunodominant Epitopes | 4 | 2010 | 50 | 0.240 |
Why?
|
| Up-Regulation | 8 | 2020 | 862 | 0.230 |
Why?
|
| ErbB Receptors | 4 | 2017 | 283 | 0.230 |
Why?
|
| Polyvinyls | 1 | 2004 | 13 | 0.230 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2004 | 24 | 0.230 |
Why?
|
| Registries | 3 | 2023 | 1398 | 0.230 |
Why?
|
| MART-1 Antigen | 5 | 2024 | 13 | 0.230 |
Why?
|
| Mass Screening | 3 | 2022 | 787 | 0.230 |
Why?
|
| Monocytes | 6 | 2002 | 346 | 0.230 |
Why?
|
| Research Design | 4 | 2018 | 679 | 0.230 |
Why?
|
| Disease Management | 3 | 2018 | 515 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2008 | 195 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 617 | 0.220 |
Why?
|
| RNA, Messenger | 7 | 2017 | 2815 | 0.220 |
Why?
|
| Medical Oncology | 3 | 2021 | 215 | 0.220 |
Why?
|
| United States Food and Drug Administration | 6 | 2018 | 149 | 0.220 |
Why?
|
| Administration, Oral | 4 | 2020 | 671 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 7 | 2018 | 605 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 94 | 0.220 |
Why?
|
| Statistics as Topic | 2 | 2002 | 251 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 4367 | 0.200 |
Why?
|
| Pyridines | 4 | 2018 | 224 | 0.200 |
Why?
|
| Telomere Homeostasis | 1 | 2022 | 42 | 0.200 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 2024 | 39 | 0.200 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 8 | 0.200 |
Why?
|
| Herpesvirus 1, Human | 1 | 2022 | 26 | 0.200 |
Why?
|
| Telomere-Binding Proteins | 1 | 2022 | 43 | 0.200 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 133 | 0.200 |
Why?
|
| Cell Differentiation | 4 | 2024 | 1912 | 0.200 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 96 | 0.190 |
Why?
|
| Gangliosides | 2 | 2000 | 69 | 0.190 |
Why?
|
| Antigen Presentation | 7 | 2019 | 103 | 0.190 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2013 | 77 | 0.190 |
Why?
|
| Fatigue | 4 | 2020 | 218 | 0.190 |
Why?
|
| Genes, p16 | 1 | 2021 | 13 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 132 | 0.190 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 136 | 0.190 |
Why?
|
| Plasma | 2 | 2021 | 96 | 0.190 |
Why?
|
| Antibodies, Neoplasm | 5 | 2007 | 58 | 0.190 |
Why?
|
| Vaccines, Synthetic | 2 | 2020 | 312 | 0.190 |
Why?
|
| Proteome | 2 | 2021 | 236 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 164 | 0.190 |
Why?
|
| Rhabdomyolysis | 1 | 2001 | 36 | 0.190 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 1995 | 7 | 0.190 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2012 | 12 | 0.190 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 2114 | 0.180 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 265 | 0.180 |
Why?
|
| Tanning | 1 | 2020 | 1 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 4 | 2017 | 157 | 0.180 |
Why?
|
| Decision Making | 1 | 2006 | 652 | 0.180 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2020 | 4 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 198 | 0.180 |
Why?
|
| Flow Cytometry | 5 | 2017 | 803 | 0.180 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2020 | 13 | 0.180 |
Why?
|
| Child | 15 | 2024 | 24259 | 0.180 |
Why?
|
| Public Health | 1 | 2023 | 260 | 0.180 |
Why?
|
| Carmustine | 3 | 1999 | 26 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2019 | 57 | 0.180 |
Why?
|
| History, 18th Century | 1 | 2020 | 69 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 5 | 2007 | 502 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 4 | 2012 | 105 | 0.180 |
Why?
|
| Internationality | 3 | 2018 | 129 | 0.180 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2020 | 16 | 0.180 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2010 | 15 | 0.170 |
Why?
|
| History, 19th Century | 1 | 2020 | 116 | 0.170 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 98 | 0.170 |
Why?
|
| Breast Neoplasms | 8 | 2009 | 2478 | 0.170 |
Why?
|
| Incidence | 3 | 2020 | 3053 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 96 | 0.170 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 2844 | 0.170 |
Why?
|
| Phenylbutyrates | 2 | 2017 | 58 | 0.170 |
Why?
|
| Cell-Derived Microparticles | 1 | 2020 | 31 | 0.170 |
Why?
|
| Chemoprevention | 1 | 2020 | 57 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2018 | 7 | 0.170 |
Why?
|
| Piperazines | 2 | 2019 | 229 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2020 | 91 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 267 | 0.170 |
Why?
|
| DNA Methylation | 4 | 2017 | 989 | 0.170 |
Why?
|
| Mitosis | 2 | 2013 | 238 | 0.170 |
Why?
|
| Self-Examination | 1 | 2019 | 7 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 269 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 269 | 0.160 |
Why?
|
| Epitopes | 5 | 2012 | 430 | 0.160 |
Why?
|
| Hemocyanins | 2 | 2014 | 27 | 0.160 |
Why?
|
| Logistic Models | 2 | 2020 | 1801 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Interferon-beta | 2 | 2015 | 51 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2017 | 53 | 0.160 |
Why?
|
| Down-Regulation | 6 | 2018 | 697 | 0.160 |
Why?
|
| Steroid Hydroxylases | 1 | 2019 | 20 | 0.160 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2019 | 21 | 0.160 |
Why?
|
| Virus Activation | 1 | 2019 | 86 | 0.160 |
Why?
|
| Models, Biological | 3 | 2014 | 1449 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 151 | 0.160 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 409 | 0.160 |
Why?
|
| Phenotype | 6 | 2014 | 4227 | 0.160 |
Why?
|
| Protein Engineering | 1 | 2019 | 73 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2020 | 381 | 0.160 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1998 | 18 | 0.160 |
Why?
|
| Hemangioblastoma | 1 | 1998 | 12 | 0.160 |
Why?
|
| Trans-Activators | 2 | 2003 | 809 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 11 | 2008 | 1063 | 0.160 |
Why?
|
| Congresses as Topic | 2 | 2010 | 169 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 66 | 0.150 |
Why?
|
| Skin Ulcer | 3 | 2017 | 32 | 0.150 |
Why?
|
| Sulfoxides | 1 | 2018 | 10 | 0.150 |
Why?
|
| Capsules | 1 | 2018 | 21 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 4 | 2019 | 263 | 0.150 |
Why?
|
| Information Dissemination | 1 | 2020 | 189 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 4 | 2014 | 261 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2015 | 4701 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2018 | 36 | 0.150 |
Why?
|
| Research | 2 | 2011 | 263 | 0.150 |
Why?
|
| Hospital Administrators | 1 | 2018 | 8 | 0.150 |
Why?
|
| Base Sequence | 7 | 2016 | 3091 | 0.150 |
Why?
|
| Central Tolerance | 1 | 2017 | 1 | 0.150 |
Why?
|
| Thrombocytopenia | 4 | 2011 | 226 | 0.150 |
Why?
|
| Tuberculosis | 2 | 2019 | 513 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 605 | 0.150 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1997 | 10 | 0.150 |
Why?
|
| Medical Records | 1 | 2018 | 190 | 0.150 |
Why?
|
| Colonic Neoplasms | 4 | 2020 | 246 | 0.150 |
Why?
|
| Transcription, Genetic | 2 | 2021 | 1703 | 0.140 |
Why?
|
| Education, Nursing, Continuing | 1 | 2017 | 19 | 0.140 |
Why?
|
| Picibanil | 1 | 1997 | 4 | 0.140 |
Why?
|
| Tissue Distribution | 1 | 2018 | 383 | 0.140 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 1142 | 0.140 |
Why?
|
| Dermatology | 1 | 2017 | 34 | 0.140 |
Why?
|
| Osteopontin | 1 | 2017 | 49 | 0.140 |
Why?
|
| RGS Proteins | 1 | 2017 | 47 | 0.140 |
Why?
|
| Aging | 1 | 2004 | 1185 | 0.140 |
Why?
|
| RNA | 1 | 2020 | 570 | 0.140 |
Why?
|
| Immune System | 2 | 2015 | 87 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2016 | 135 | 0.140 |
Why?
|
| Vaccines, DNA | 2 | 2012 | 48 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2017 | 85 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2017 | 373 | 0.130 |
Why?
|
| Streptozocin | 1 | 1996 | 24 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 810 | 0.130 |
Why?
|
| Amino Acid Sequence | 9 | 2012 | 2695 | 0.130 |
Why?
|
| Inflammation | 2 | 2021 | 1405 | 0.130 |
Why?
|
| Tonsillar Neoplasms | 1 | 1996 | 7 | 0.130 |
Why?
|
| Palatal Neoplasms | 1 | 1996 | 5 | 0.130 |
Why?
|
| Dermatitis | 1 | 2016 | 25 | 0.130 |
Why?
|
| Fluorouracil | 4 | 1998 | 128 | 0.130 |
Why?
|
| Interleukin-10 | 2 | 2015 | 172 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 299 | 0.130 |
Why?
|
| Molecular Sequence Data | 10 | 2011 | 3867 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 52 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2023 | 1553 | 0.130 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2015 | 12 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 69 | 0.130 |
Why?
|
| Nevus of Ota | 1 | 2015 | 2 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 172 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 373 | 0.130 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 4 | 2022 | 13 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 1995 | 45 | 0.120 |
Why?
|
| Liver Neoplasms | 4 | 2004 | 1311 | 0.120 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2018 | 754 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2023 | 940 | 0.120 |
Why?
|
| Compassionate Use Trials | 1 | 2014 | 14 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2017 | 345 | 0.120 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2012 | 5 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 26 | 0.120 |
Why?
|
| Hearing Loss | 1 | 2016 | 131 | 0.120 |
Why?
|
| Nitrosourea Compounds | 2 | 2005 | 4 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2016 | 161 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 323 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 366 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2014 | 10 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 2054 | 0.120 |
Why?
|
| Patient Rights | 1 | 2014 | 50 | 0.120 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 22 | 0.110 |
Why?
|
| Monophenol Monooxygenase | 2 | 2012 | 20 | 0.110 |
Why?
|
| Recurrence | 2 | 2010 | 1418 | 0.110 |
Why?
|
| Lymphoma | 3 | 2009 | 322 | 0.110 |
Why?
|
| Patient Safety | 2 | 2017 | 397 | 0.110 |
Why?
|
| Social Support | 3 | 1992 | 344 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 1584 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2006 | 1012 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2018 | 555 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 3 | 2017 | 330 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 789 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 183 | 0.110 |
Why?
|
| Interleukins | 3 | 2007 | 118 | 0.110 |
Why?
|
| Diarrhea | 3 | 2023 | 315 | 0.110 |
Why?
|
| Tetanus | 1 | 2013 | 21 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 152 | 0.110 |
Why?
|
| Lipids | 2 | 2013 | 513 | 0.110 |
Why?
|
| Adenocarcinoma | 6 | 2020 | 994 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 501 | 0.110 |
Why?
|
| DNA Primers | 2 | 2012 | 660 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 192 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2024 | 467 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 827 | 0.110 |
Why?
|
| Bone Neoplasms | 3 | 2014 | 431 | 0.100 |
Why?
|
| Merkel cell polyomavirus | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mitolactol | 2 | 1983 | 2 | 0.100 |
Why?
|
| Antigens, Surface | 3 | 2010 | 121 | 0.100 |
Why?
|
| MicroRNAs | 2 | 2010 | 829 | 0.100 |
Why?
|
| Mitochondria | 2 | 2012 | 676 | 0.100 |
Why?
|
| Gene Expression | 2 | 2017 | 1565 | 0.100 |
Why?
|
| Antibodies | 3 | 2015 | 371 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 177 | 0.100 |
Why?
|
| Polyomavirus Infections | 2 | 2012 | 90 | 0.100 |
Why?
|
| Cetuximab | 1 | 2012 | 12 | 0.100 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 18 | 0.100 |
Why?
|
| Risk | 4 | 2010 | 747 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 664 | 0.100 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 18 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2012 | 25 | 0.100 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1992 | 3 | 0.100 |
Why?
|
| Salvage Therapy | 3 | 2020 | 193 | 0.100 |
Why?
|
| Interleukin-12 | 3 | 2011 | 113 | 0.100 |
Why?
|
| Vinblastine | 4 | 2017 | 48 | 0.100 |
Why?
|
| Anxiety | 1 | 2018 | 959 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2012 | 63 | 0.100 |
Why?
|
| Sick Role | 1 | 1992 | 31 | 0.100 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Alemtuzumab | 1 | 2012 | 88 | 0.100 |
Why?
|
| Receptors, Estrogen | 3 | 2009 | 791 | 0.100 |
Why?
|
| Mastectomy, Segmental | 1 | 1992 | 27 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2011 | 19 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2007 | 126 | 0.100 |
Why?
|
| Trastuzumab | 1 | 2012 | 131 | 0.100 |
Why?
|
| Gene Transfer Techniques | 2 | 2012 | 357 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2011 | 60 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 39 | 0.100 |
Why?
|
| Immunization | 2 | 2010 | 307 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 44 | 0.100 |
Why?
|
| Health | 1 | 2011 | 37 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 53 | 0.090 |
Why?
|
| Melanosis | 1 | 1991 | 10 | 0.090 |
Why?
|
| Blood Donors | 1 | 2011 | 62 | 0.090 |
Why?
|
| Agranulocytosis | 1 | 1991 | 14 | 0.090 |
Why?
|
| World Health Organization | 1 | 2011 | 100 | 0.090 |
Why?
|
| Sunlight | 1 | 1991 | 23 | 0.090 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 35 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 1289 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 146 | 0.090 |
Why?
|
| Vitiligo | 3 | 2008 | 6 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 131 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2015 | 3046 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 136 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2019 | 327 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 754 | 0.090 |
Why?
|
| Age Factors | 6 | 2019 | 2811 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2011 | 402 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 13 | 0.090 |
Why?
|
| Genes, MHC Class II | 1 | 2010 | 33 | 0.090 |
Why?
|
| Obesity | 2 | 2023 | 2235 | 0.090 |
Why?
|
| Olea | 1 | 2010 | 1 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 239 | 0.090 |
Why?
|
| Fats | 1 | 2010 | 13 | 0.090 |
Why?
|
| Forecasting | 2 | 2011 | 354 | 0.090 |
Why?
|
| HLA-DR4 Antigen | 2 | 2000 | 6 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 254 | 0.090 |
Why?
|
| Clone Cells | 4 | 2006 | 163 | 0.090 |
Why?
|
| Proteomics | 2 | 2014 | 479 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 113 | 0.090 |
Why?
|
| Random Allocation | 7 | 1990 | 433 | 0.080 |
Why?
|
| Tachycardia | 1 | 2010 | 68 | 0.080 |
Why?
|
| Naphthoquinones | 1 | 2009 | 5 | 0.080 |
Why?
|
| Ulcer | 2 | 2017 | 48 | 0.080 |
Why?
|
| Sample Size | 2 | 2008 | 85 | 0.080 |
Why?
|
| Genome | 1 | 2012 | 474 | 0.080 |
Why?
|
| Nausea | 3 | 2023 | 97 | 0.080 |
Why?
|
| Polyomavirus | 1 | 2009 | 32 | 0.080 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 31 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2009 | 335 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1990 | 99 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 595 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2012 | 471 | 0.080 |
Why?
|
| Iceland | 1 | 2009 | 11 | 0.080 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2009 | 87 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2024 | 13918 | 0.080 |
Why?
|
| RNA, Neoplasm | 3 | 2004 | 138 | 0.080 |
Why?
|
| Tamoxifen | 3 | 1999 | 363 | 0.080 |
Why?
|
| Social Environment | 1 | 1990 | 120 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 562 | 0.080 |
Why?
|
| Pregnancy | 2 | 2020 | 7129 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2009 | 132 | 0.080 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2008 | 16 | 0.080 |
Why?
|
| Fibronectins | 1 | 2009 | 102 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2007 | 318 | 0.080 |
Why?
|
| Vaccines, Conjugate | 2 | 2001 | 78 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 715 | 0.080 |
Why?
|
| Body Weight | 2 | 2011 | 1007 | 0.080 |
Why?
|
| Injections, Intramuscular | 4 | 2018 | 191 | 0.080 |
Why?
|
| Italy | 3 | 2014 | 111 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 3677 | 0.080 |
Why?
|
| Autophagy | 2 | 2024 | 390 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 1992 | 459 | 0.080 |
Why?
|
| Arsenicals | 1 | 2008 | 15 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2012 | 939 | 0.080 |
Why?
|
| Oxides | 1 | 2008 | 15 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 244 | 0.070 |
Why?
|
| Mycoplasma penetrans | 1 | 2007 | 1 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 12 | 0.070 |
Why?
|
| Cell Movement | 2 | 2011 | 831 | 0.070 |
Why?
|
| Indium | 1 | 1987 | 8 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2007 | 40 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 43 | 0.070 |
Why?
|
| Endostatins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Radioisotopes | 1 | 1987 | 38 | 0.070 |
Why?
|
| HLA-DRB1 Chains | 3 | 2003 | 37 | 0.070 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2018 | 18 | 0.070 |
Why?
|
| Dimerization | 1 | 2007 | 144 | 0.070 |
Why?
|
| Pruritus | 2 | 2020 | 41 | 0.070 |
Why?
|
| Poly I-C | 2 | 2011 | 23 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 194 | 0.070 |
Why?
|
| Benchmarking | 1 | 2008 | 132 | 0.070 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2007 | 35 | 0.070 |
Why?
|
| Neutropenia | 3 | 2003 | 202 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 60 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 182 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 101 | 0.070 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Hypopigmentation | 1 | 2006 | 11 | 0.070 |
Why?
|
| Remission Induction | 5 | 1997 | 299 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 232 | 0.070 |
Why?
|
| Algorithms | 2 | 2011 | 1598 | 0.060 |
Why?
|
| Methionine | 1 | 2006 | 103 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 186 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 22 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 202 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 1990 | 867 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1479 | 0.060 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 70 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2006 | 61 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2006 | 134 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 146 | 0.060 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 682 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1999 | 577 | 0.060 |
Why?
|
| Infusions, Intravenous | 4 | 2009 | 539 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2007 | 833 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 268 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2005 | 5 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2005 | 51 | 0.060 |
Why?
|
| Cell Line | 6 | 2007 | 2772 | 0.060 |
Why?
|
| Interleukin-1 | 2 | 2002 | 143 | 0.060 |
Why?
|
| Protein Binding | 4 | 2014 | 1741 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 2 | 2003 | 86 | 0.060 |
Why?
|
| Placebos | 2 | 2019 | 241 | 0.060 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2024 | 19 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 352 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1878 | 0.060 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2024 | 19 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2024 | 27 | 0.060 |
Why?
|
| High Mobility Group Proteins | 1 | 2024 | 32 | 0.060 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2024 | 9 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 488 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 2003 | 967 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2004 | 27 | 0.060 |
Why?
|
| Sarcoma, Kaposi | 2 | 2002 | 120 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2024 | 56 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 204 | 0.060 |
Why?
|
| Amifostine | 1 | 2003 | 14 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 1984 | 94 | 0.060 |
Why?
|
| Multiple Myeloma | 2 | 2002 | 169 | 0.060 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 35 | 0.060 |
Why?
|
| Semustine | 1 | 1983 | 1 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 1983 | 5 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2004 | 78 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 58 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2007 | 529 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2004 | 279 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2022 | 458 | 0.050 |
Why?
|
| Genotype | 3 | 2014 | 2537 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2009 | 115 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2017 | 1102 | 0.050 |
Why?
|
| Ligands | 2 | 2014 | 533 | 0.050 |
Why?
|
| Lymphangitis | 1 | 1982 | 5 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2024 | 300 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 30 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2002 | 19 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 1013 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2002 | 32 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 878 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1996 | 178 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2001 | 256 | 0.050 |
Why?
|
| Bone Marrow | 1 | 1984 | 324 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2002 | 48 | 0.050 |
Why?
|
| Thrombocytosis | 1 | 2002 | 34 | 0.050 |
Why?
|
| Polycythemia Vera | 1 | 2002 | 37 | 0.050 |
Why?
|
| Receptors, Interferon | 2 | 2017 | 25 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 98 | 0.050 |
Why?
|
| Reoperation | 2 | 2007 | 819 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2017 | 677 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 425 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 77 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2011 | 1611 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2003 | 1168 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2002 | 125 | 0.050 |
Why?
|
| Saponins | 1 | 2001 | 22 | 0.050 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 1992 | 8 | 0.050 |
Why?
|
| Observer Variation | 2 | 1992 | 300 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2001 | 17 | 0.050 |
Why?
|
| Contactin 1 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Leucovorin | 1 | 1981 | 50 | 0.050 |
Why?
|
| Telomere | 1 | 2022 | 206 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2002 | 408 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 510 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2001 | 6 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2021 | 28 | 0.050 |
Why?
|
| Polylysine | 1 | 2001 | 10 | 0.050 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2001 | 12 | 0.050 |
Why?
|
| Guanosine | 1 | 2000 | 11 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 442 | 0.050 |
Why?
|
| Levamisole | 1 | 2000 | 4 | 0.050 |
Why?
|
| Leg | 3 | 1995 | 155 | 0.050 |
Why?
|
| Regression Analysis | 4 | 1996 | 772 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2019 | 796 | 0.040 |
Why?
|
| ADAM10 Protein | 1 | 2020 | 10 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2002 | 478 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2022 | 482 | 0.040 |
Why?
|
| Kinetics | 3 | 1991 | 1318 | 0.040 |
Why?
|
| Exanthema | 1 | 2021 | 68 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 39 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 66 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 2000 | 31 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 98 | 0.040 |
Why?
|
| Benzenesulfonates | 2 | 2012 | 11 | 0.040 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 33 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 137 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1996 | 106 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 210 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2012 | 134 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 69 | 0.040 |
Why?
|
| Transaminases | 1 | 2020 | 32 | 0.040 |
Why?
|
| Infusions, Parenteral | 3 | 1997 | 100 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2013 | 79 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2024 | 8114 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 103 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2021 | 209 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 358 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 76 | 0.040 |
Why?
|
| Etoposide | 1 | 2000 | 117 | 0.040 |
Why?
|
| Biological Availability | 1 | 2000 | 133 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 62 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 328 | 0.040 |
Why?
|
| Nervous System Diseases | 2 | 1996 | 372 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 547 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2017 | 696 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2001 | 243 | 0.040 |
Why?
|
| Cell Survival | 2 | 2017 | 806 | 0.040 |
Why?
|
| Comorbidity | 1 | 2004 | 1497 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 1999 | 45 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 1093 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 101 | 0.040 |
Why?
|
| Keratin-20 | 2 | 2012 | 13 | 0.040 |
Why?
|
| Oxysterols | 1 | 2019 | 2 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2019 | 45 | 0.040 |
Why?
|
| Reserpine | 1 | 2019 | 12 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 228 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2019 | 26 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 53 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 21 | 0.040 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 31 | 0.040 |
Why?
|
| Methotrexate | 1 | 1981 | 343 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2011 | 233 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 2 | 2009 | 51 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 54 | 0.040 |
Why?
|
| Oleic Acids | 2 | 2008 | 9 | 0.040 |
Why?
|
| Transfection | 3 | 2009 | 1068 | 0.040 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1998 | 12 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 311 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 125 | 0.040 |
Why?
|
| Endothelium | 1 | 1998 | 72 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 221 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2020 | 330 | 0.040 |
Why?
|
| Mannitol | 2 | 2008 | 48 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 117 | 0.040 |
Why?
|
| Esophageal Neoplasms | 2 | 2004 | 359 | 0.040 |
Why?
|
| Genetic Therapy | 2 | 2000 | 679 | 0.040 |
Why?
|
| Receptor, ErbB-4 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2002 | 323 | 0.040 |
Why?
|
| Surgical Oncology | 1 | 2017 | 11 | 0.040 |
Why?
|
| Beclin-1 | 1 | 2017 | 26 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 300 | 0.040 |
Why?
|
| Sex Factors | 3 | 2018 | 1265 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 84 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 51 | 0.040 |
Why?
|
| Aminopterin | 1 | 1997 | 3 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Granulocytes | 2 | 2002 | 65 | 0.040 |
Why?
|
| Histone Deacetylase 6 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Hypoxia | 1 | 2019 | 248 | 0.040 |
Why?
|
| Indazoles | 1 | 2017 | 23 | 0.040 |
Why?
|
| Herpesviridae | 1 | 2017 | 31 | 0.040 |
Why?
|
| Hypotension | 3 | 2003 | 177 | 0.040 |
Why?
|
| Superoxides | 1 | 1997 | 154 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2001 | 547 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 177 | 0.030 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 1996 | 17 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2002 | 744 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2017 | 164 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2017 | 52 | 0.030 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 47 | 0.030 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1996 | 5 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 2010 | 202 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 369 | 0.030 |
Why?
|
| Melanoma-Specific Antigens | 2 | 1987 | 8 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2854 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2013 | 472 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 26 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 114 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1984 | 2058 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 74 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1996 | 268 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2020 | 884 | 0.030 |
Why?
|
| Melanins | 1 | 2015 | 18 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 28 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2009 | 314 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1987 | 151 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 1474 | 0.030 |
Why?
|
| Genes, ras | 1 | 2015 | 96 | 0.030 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Liver | 1 | 2002 | 1743 | 0.030 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2015 | 13 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 229 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 496 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 355 | 0.030 |
Why?
|
| Spumavirus | 1 | 1994 | 1 | 0.030 |
Why?
|
| Pongo pygmaeus | 1 | 1994 | 7 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 421 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 161 | 0.030 |
Why?
|
| Glutathione | 1 | 1996 | 195 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 666 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2397 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 84 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 76 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2014 | 17 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1099 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2013 | 1171 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2014 | 44 | 0.030 |
Why?
|
| Glucose | 1 | 2019 | 880 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 518 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2004 | 101 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 55 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 56 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1985 | 247 | 0.030 |
Why?
|
| Binding Sites | 2 | 2009 | 1294 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 112 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 1994 | 40 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2013 | 58 | 0.030 |
Why?
|
| Biological Assay | 2 | 1985 | 100 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 738 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 1994 | 46 | 0.030 |
Why?
|
| Blood Cell Count | 2 | 2002 | 69 | 0.030 |
Why?
|
| Ricin | 1 | 1993 | 12 | 0.030 |
Why?
|
| Immunotoxins | 1 | 1993 | 21 | 0.030 |
Why?
|
| New Hampshire | 1 | 1993 | 6 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 96 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 236 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 2005 | 75 | 0.030 |
Why?
|
| Epidermis | 1 | 1993 | 59 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 399 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 340 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2012 | 47 | 0.030 |
Why?
|
| Virus Integration | 1 | 2012 | 42 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2012 | 24 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 2012 | 48 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2013 | 33 | 0.030 |
Why?
|
| Alleles | 2 | 2009 | 1602 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 178 | 0.030 |
Why?
|
| Pathology | 1 | 1992 | 39 | 0.030 |
Why?
|
| Hydrazines | 1 | 2012 | 28 | 0.030 |
Why?
|
| Piperidines | 1 | 2014 | 202 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1993 | 146 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 1465 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2015 | 674 | 0.030 |
Why?
|
| Australia | 2 | 2010 | 138 | 0.020 |
Why?
|
| Haplotypes | 1 | 2014 | 517 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 93 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 254 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 285 | 0.020 |
Why?
|
| Cell Separation | 2 | 2010 | 230 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 61 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 667 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1992 | 23 | 0.020 |
Why?
|
| Immunity | 2 | 1983 | 179 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1991 | 39 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2011 | 61 | 0.020 |
Why?
|
| Bone Marrow Diseases | 2 | 1997 | 40 | 0.020 |
Why?
|
| Connecticut | 1 | 1991 | 20 | 0.020 |
Why?
|
| Chemokine CCL21 | 1 | 2011 | 4 | 0.020 |
Why?
|
| CD11 Antigens | 1 | 1991 | 12 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 569 | 0.020 |
Why?
|
| Personality Inventory | 1 | 1992 | 166 | 0.020 |
Why?
|
| Colitis | 1 | 2013 | 153 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 412 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1999 | 254 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3726 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 239 | 0.020 |
Why?
|
| Leukopenia | 1 | 1991 | 44 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 340 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 678 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2010 | 56 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2010 | 14 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 66 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 273 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2011 | 124 | 0.020 |
Why?
|
| Intraoperative Care | 3 | 2000 | 103 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 1990 | 21 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 1990 | 103 | 0.020 |
Why?
|
| Glioblastoma | 2 | 1984 | 334 | 0.020 |
Why?
|
| Psychoneuroimmunology | 1 | 1990 | 2 | 0.020 |
Why?
|
| Sirolimus | 1 | 2012 | 220 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2010 | 148 | 0.020 |
Why?
|
| Social Class | 1 | 1991 | 190 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3383 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1987 | 257 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 45 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 108 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 28 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1988 | 202 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 142 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 156 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12376 | 0.020 |
Why?
|
| Software | 1 | 2014 | 675 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 349 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 132 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 313 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1991 | 218 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 2019 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 400 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 458 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 586 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 657 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4296 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Education | 1 | 2008 | 105 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2009 | 479 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2007 | 59 | 0.020 |
Why?
|
| Vincristine | 1 | 2008 | 196 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 440 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 456 | 0.020 |
Why?
|
| Cimetidine | 1 | 1987 | 14 | 0.020 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1987 | 16 | 0.020 |
Why?
|
| Coumarins | 1 | 1987 | 23 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2586 | 0.020 |
Why?
|
| Carcinoma | 1 | 1990 | 278 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2007 | 52 | 0.020 |
Why?
|
| Axilla | 1 | 2006 | 38 | 0.020 |
Why?
|
| Peptide Library | 1 | 2007 | 55 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 197 | 0.020 |
Why?
|
| Arm | 2 | 1984 | 75 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 289 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 422 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 1986 | 26 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 16 | 0.020 |
Why?
|
| Immunoassay | 2 | 2002 | 124 | 0.020 |
Why?
|
| Health Education | 1 | 2008 | 225 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1991 | 561 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1985 | 110 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 2 | 1997 | 334 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 1985 | 32 | 0.020 |
Why?
|
| HLA-DP beta-Chains | 1 | 2005 | 9 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 321 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 293 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2005 | 74 | 0.020 |
Why?
|
| Hair Color | 1 | 1984 | 12 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 1245 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1984 | 6 | 0.010 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1984 | 16 | 0.010 |
Why?
|
| Papilloma | 1 | 1984 | 25 | 0.010 |
Why?
|
| Mouth Diseases | 1 | 1984 | 11 | 0.010 |
Why?
|
| Centrifugation | 1 | 2004 | 25 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 98 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2004 | 27 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2004 | 54 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1984 | 28 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2003 | 17 | 0.010 |
Why?
|
| Enzymes | 1 | 2004 | 52 | 0.010 |
Why?
|
| Bleomycin | 1 | 1984 | 150 | 0.010 |
Why?
|
| Biotransformation | 1 | 1983 | 49 | 0.010 |
Why?
|
| Uvea | 1 | 1983 | 3 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1983 | 40 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 1984 | 79 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2008 | 481 | 0.010 |
Why?
|
| Hemolytic Plaque Technique | 1 | 1983 | 6 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1983 | 39 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1998 | 25 | 0.010 |
Why?
|
| Endocrine Glands | 1 | 1983 | 10 | 0.010 |
Why?
|
| Survivors | 1 | 2005 | 344 | 0.010 |
Why?
|
| Syndrome | 1 | 1986 | 1116 | 0.010 |
Why?
|
| Hypertension | 1 | 1991 | 1284 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2003 | 210 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1984 | 165 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2003 | 17 | 0.010 |
Why?
|
| Oxygen Radioisotopes | 1 | 2002 | 4 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1984 | 77 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 43 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1982 | 73 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1983 | 140 | 0.010 |
Why?
|
| CD11b Antigen | 1 | 2002 | 37 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1985 | 298 | 0.010 |
Why?
|
| Extremities | 1 | 1982 | 83 | 0.010 |
Why?
|
| Creatinine | 1 | 1984 | 382 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2001 | 30 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 185 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 29 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 206 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 211 | 0.010 |
Why?
|
| Histamine | 1 | 2002 | 44 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2003 | 133 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1985 | 459 | 0.010 |
Why?
|
| Steroids | 1 | 1982 | 203 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2001 | 31 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1984 | 258 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 54 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 449 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1984 | 237 | 0.010 |
Why?
|
| Clinical Nursing Research | 1 | 2000 | 6 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2000 | 85 | 0.010 |
Why?
|
| Leukemia | 1 | 1984 | 375 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2008 | 824 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 164 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2000 | 22 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2001 | 105 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2000 | 138 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 604 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 96 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2000 | 66 | 0.010 |
Why?
|
| Sepsis | 1 | 1984 | 476 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1999 | 67 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2001 | 260 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1984 | 545 | 0.010 |
Why?
|
| Influenza, Human | 1 | 1985 | 652 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 297 | 0.010 |
Why?
|
| Mitomycin | 1 | 1998 | 49 | 0.010 |
Why?
|
| Quality Control | 1 | 1998 | 119 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2000 | 395 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1326 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2001 | 378 | 0.010 |
Why?
|
| Models, Econometric | 1 | 1997 | 9 | 0.010 |
Why?
|
| Stomatitis | 1 | 1997 | 13 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 1998 | 158 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1996 | 4 | 0.010 |
Why?
|
| CD146 Antigen | 1 | 1996 | 7 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1998 | 141 | 0.010 |
Why?
|
| Markov Chains | 1 | 1997 | 83 | 0.010 |
Why?
|
| Bisbenzimidazole | 1 | 1996 | 4 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1981 | 478 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1996 | 79 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1996 | 27 | 0.010 |
Why?
|
| Color | 1 | 1996 | 30 | 0.010 |
Why?
|
| Automation | 1 | 1996 | 59 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1996 | 224 | 0.010 |
Why?
|
| Cognition | 1 | 2000 | 738 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1996 | 260 | 0.010 |
Why?
|
| Injections, Intralymphatic | 1 | 1994 | 1 | 0.010 |
Why?
|
| Iris Diseases | 2 | 1985 | 15 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3549 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1997 | 280 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1994 | 46 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 1739 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1988 | 313 | 0.000 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1986 | 15 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1986 | 68 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1986 | 45 | 0.000 |
Why?
|
| Cell Division | 1 | 1986 | 781 | 0.000 |
Why?
|
| Procarbazine | 1 | 1984 | 13 | 0.000 |
Why?
|
| Microwaves | 1 | 1984 | 6 | 0.000 |
Why?
|
| Prednisolone | 1 | 1984 | 72 | 0.000 |
Why?
|
| Methylprednisolone | 1 | 1984 | 90 | 0.000 |
Why?
|
| Glioma | 1 | 1988 | 496 | 0.000 |
Why?
|
| Neuroblastoma | 1 | 1988 | 519 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1984 | 103 | 0.000 |
Why?
|
| Leukocytes | 1 | 1984 | 206 | 0.000 |
Why?
|
| Retinal Diseases | 1 | 1985 | 172 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1984 | 892 | 0.000 |
Why?
|
| Fever | 1 | 1984 | 296 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1982 | 348 | 0.000 |
Why?
|